These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 27307466)
1. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women. Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466 [TBL] [Abstract][Full Text] [Related]
2. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer. Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749 [TBL] [Abstract][Full Text] [Related]
3. Reproductive characteristics, menopausal status, race and ethnicity, and risk of breast cancer subtypes defined by ER, PR and HER2 status: the Breast Cancer Etiology in Minorities study. John EM; Koo J; Phipps AI; Longacre TA; Kurian AW; Ingles SA; Wu AH; Hines LM Breast Cancer Res; 2024 May; 26(1):88. PubMed ID: 38822357 [TBL] [Abstract][Full Text] [Related]
4. Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer. Baglia ML; Cook LS; Mei-Tzu C; Wiggins C; Hill D; Porter P; Li CI Int J Cancer; 2018 Oct; 143(8):1849-1857. PubMed ID: 29708591 [TBL] [Abstract][Full Text] [Related]
5. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program. Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999 [TBL] [Abstract][Full Text] [Related]
6. Reproductive Risk Factors Associated with Breast Cancer Molecular Subtypes among Young Women in Northern China. Wang JM; Wang J; Zhao HG; Liu TT; Wang FY Biomed Res Int; 2020; 2020():5931529. PubMed ID: 32337260 [TBL] [Abstract][Full Text] [Related]
7. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years. Kawai M; Malone KE; Tang MT; Li CI Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704 [TBL] [Abstract][Full Text] [Related]
8. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009-2016: a cross-sectional study. Chitkara A; Mesa-Eguiagaray I; Wild SH; Hall PS; Cameron DA; Sims AH; Figueroa JD Breast Cancer Res Treat; 2022 Nov; 196(2):379-387. PubMed ID: 36116093 [TBL] [Abstract][Full Text] [Related]
9. Association between common risk factors and molecular subtypes in breast cancer patients. Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K Breast; 2013 Jun; 22(3):344-50. PubMed ID: 22981738 [TBL] [Abstract][Full Text] [Related]
10. Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. Phipps AI; Chlebowski RT; Prentice R; McTiernan A; Wactawski-Wende J; Kuller LH; Adams-Campbell LL; Lane D; Stefanick ML; Vitolins M; Kabat GC; Rohan TE; Li CI J Natl Cancer Inst; 2011 Mar; 103(6):470-7. PubMed ID: 21346227 [TBL] [Abstract][Full Text] [Related]
11. Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. Clarke CA; Keegan TH; Yang J; Press DJ; Kurian AW; Patel AH; Lacey JV J Natl Cancer Inst; 2012 Jul; 104(14):1094-101. PubMed ID: 22773826 [TBL] [Abstract][Full Text] [Related]
12. Associations of hormone-related factors with breast cancer risk according to hormone receptor status among white and African American women. Cui Y; Deming-Halverson SL; Shrubsole MJ; Beeghly-Fadiel A; Fair AM; Sanderson M; Shu XO; Kelley MC; Zheng W Clin Breast Cancer; 2014 Dec; 14(6):417-25. PubMed ID: 24970715 [TBL] [Abstract][Full Text] [Related]
13. Breast feeding, parity and breast cancer subtypes in a Spanish cohort. Redondo CM; Gago-Domínguez M; Ponte SM; Castelo ME; Jiang X; García AA; Fernández MP; Tomé MA; Fraga M; Gude F; Martínez ME; Garzón VM; Carracedo Á; Castelao JE PLoS One; 2012; 7(7):e40543. PubMed ID: 22792365 [TBL] [Abstract][Full Text] [Related]
14. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer. Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580 [TBL] [Abstract][Full Text] [Related]
15. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study. Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840 [TBL] [Abstract][Full Text] [Related]
16. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. Howlader N; Altekruse SF; Li CI; Chen VW; Clarke CA; Ries LA; Cronin KA J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24777111 [TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor, progesterone receptor, and HER2-neu expression in first primary breast cancers and risk of second primary contralateral breast cancer. Saltzman BS; Malone KE; McDougall JA; Daling JR; Li CI Breast Cancer Res Treat; 2012 Oct; 135(3):849-55. PubMed ID: 22903686 [TBL] [Abstract][Full Text] [Related]
18. Reproductive factors and subtypes of breast cancer defined by estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2: a register-based study from Korea. Lee JS; Oh M; ; Clin Breast Cancer; 2014 Dec; 14(6):426-34. PubMed ID: 25034438 [TBL] [Abstract][Full Text] [Related]
19. A cumulative index of exposure to endogenous estrogens and breast cancer by molecular subtypes in northern Mexican women. Rojas-Lima E; Gamboa-Loira B; Cebrián ME; Rothenberg SJ; López-Carrillo L Breast Cancer Res Treat; 2020 Apr; 180(3):791-800. PubMed ID: 32086656 [TBL] [Abstract][Full Text] [Related]
20. Use of four biomarkers to evaluate the risk of breast cancer subtypes in the women's contraceptive and reproductive experiences study. Ma H; Wang Y; Sullivan-Halley J; Weiss L; Marchbanks PA; Spirtas R; Ursin G; Burkman RT; Simon MS; Malone KE; Strom BL; McDonald JA; Press MF; Bernstein L Cancer Res; 2010 Jan; 70(2):575-87. PubMed ID: 20068186 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]